Shoichi Yamamoto

Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study

Jonathan P. Piccini, Valeria Caso, Stuart J. Connolly et al. · The Lancet · 2022 · 296 citations · Full text

Thrombosis, Dose-finding Phase 2, Cardiovascular Disease +10

Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori

Akihiro Fujikawa, Daisuke Shirasaka, Shoichi Yamamoto et al. · Nature Genetics · 2003 · 249 citations

Signal Transduction, Gastrointestinal Pharmacology, Pathogenesis +9

MITOL/MARCH5 determines the susceptibility of cardiomyocytes to doxorubicin-induced ferroptosis by regulating GSH homeostasis

Hiroki Kitakata, Jin Endo, Hirokazu Matsushima et al. · Journal of Molecular and Cellular Cardiology · 2021 · 69 citations

Inflammation, Mitophagy, Cardiomyopathy +11

In vitro and in vivo studies on potentiation of cytotoxic effects of anticancer drugs or cobalt 60 gamma ray by interferon on human neoplastic cells

Masayoshi Namba, Shoichi Yamamoto, Hiroyoshi Tanaka et al. · Cancer · 1984 · 55 citations

Phase I Clinical Studies of 7432‐S, a New Oral Cephalosporin: Safety and Pharmacokinetics

M Nakashima, Toshihiko Uematsu, Yoshiharu Takiguchi et al. · The Journal of Clinical Pharmacology · 1988 · 39 citations